Robichaux et al. conducted a phase II study in 12 heavily pretreated NSCLC patients harboring HER2 exon 20 insertions with promising preliminary results; ORR was 41.7% (5 PR), DCR was 83.3%, and median PFS was 5.6 months [66]. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.